Study in Patients With COPD

The purpose of this study is to determine the efficacy and safety of the investigational drug in the treatment of COPD in comparison with a placebo.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COPD Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Research Site, Bessemer, Alabama, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Medical diagnosis of COPD
Current or prior history of cigarette smoking

Exclusion criteria

Medical diagnosis of asthma
Chest x-ray (CXR) prior to Day 1 diagnostic of significant disease other than COPD
Significant condition or disease other than COPD

Treatment and study plan

formoterol fumarate

Drug

Primary outcomes

Measure of lung function

Secondary outcomes

Change in lung function, as well as vital signs
Physical Exam results, Adverse Event reporting, etc

Sponsors and collaborators

Lead sponsor

Dey

Industry

Registry information

Important dates

Primary completion: 2005
Study completion: 2006
First posted: Sep 22, 2005
Registry last updated: Nov 11, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed